Dr. Alexei von Delwig is a distinguished immunologist whose extensive career has significantly advanced the fields of vaccine development and fundamental immunology. After graduating from medical school, he dedicated his professional life to medical immunological research across various countries, including Germany, Norway, the Netherlands, the USA, and the UK. His early work concentrated on developing vaccines against meningococcus, contributing to the prevention of meningococcal diseases. In the realm of fundamental immunology, Dr. von Delwig has explored the mechanisms of antigen processing and presentation. His research has provided insights into how major histocompatibility complex class II (MHC-II) molecules present exogenous peptides on the surface of macrophages, highlighting the role of surface-associated proteolytic enzymes in modulating this process. Dr. von Delwig's scholarly contributions include numerous publications in esteemed scientific journals. His research encompasses areas such as immunotherapeutic strategies, vaccination and immunization, and immunogenic anticancer therapies. Throughout his career, Dr. von Delwig has demonstrated a profound commitment to advancing immunological science, with a particular focus on developing vaccines and elucidating the fundamental processes of the immune system.